MicroPort Scientific (853) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was US$547.5 million, down 2.2% year-on-year (excluding FX impact), reflecting industry headwinds, external challenges, and delayed procurement cycles.

• Net loss narrowed significantly to US$36.4 million from US$106.7 million, a 65.9% year-on-year improvement, with EBITDA rising to US$127.8 million from US$59.1 million.

• Profitability improved due to cost controls, divestment of non-core businesses, and operational efficiency initiatives.

• Overseas business revenue surged 57.3% year-on-year, with strong growth in several segments.

• Adjusted (non-HKFRS) profit for the period was US$1.2 million, compared to a loss of US$64.1 million in the prior year.

Financial highlights

• Gross profit margin declined to 56.4% from 59.2% due to price reductions and sales mix changes; gross profit was US$308.6 million, down 6.7% year-on-year.

• R&D costs fell 37.3% to US$72.1 million, with the R&D cost ratio dropping from 20.6% to 13.2%.

• Distribution and administrative expenses decreased by 4.9% and 1.2%, respectively.

• Other net income rose to US$54.8 million, mainly from FX gains and government grants.

• Finance costs increased 21.8% to US$59.0 million, mainly due to higher interest expenses on convertible loans and borrowings.

• Impairment losses on non-current assets rose to US$23.4 million, mainly from equity-accounted investees.

• Net current assets stood at US$550.2 million; cash and cash equivalents were US$764.5 million.

• Total borrowings (including convertible bonds/loans) reached US$1,682.9 million; liabilities to assets ratio increased to 68.7%.

Outlook and guidance

• Management remains confident in long-term growth, focusing on innovation, global expansion, and cost control, but notes short-term macroeconomic and industry headwinds.

• Strategic restructuring of cardiac rhythm management and structural heart disease businesses is underway to build an integrated cardiovascular platform.

• Continued emphasis on risk management, lean operations, and internationalization to navigate market uncertainties.

• Plans include further integration of global operations, product portfolio diversification, and management system reform.